Superworth

Coherus Oncology PE ratio CHRS

Share price divided by earnings per share over the last twelve months, since 2020.

Today, Oct 23, 2026
n/m
losses over the last year
Last meaningful
9.1×
Apr 2021
Peer median
17.6×

Coherus Oncology has no meaningful PE ratio today: it lost $1.03 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Apr 2021, at 9.1×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
20219.1×8.5×10.0×
20208.5×7.1×16.3×

Against its peers

Companies in Healthcare nearest Coherus Oncology's size, closest first, today.

CompanyPE ratio
CHRSCoherus Oncologyn/m
PDEXPro DEX15.1×
PLXProtalix BioTherapeutics11.1×
NATRNatures Sunshine Products12.0×
ELMDElectromed20.1×
UTMDUtah Medical Products22.6×
KEQUKewaunee Scientific11.9×
ICCCImmucell128×
INFUInfuSystem34.0×
LFVNLifevantage14.7×
VMDViemed Healthcare27.2×
Peer median17.6×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Coherus Oncology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.